CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year Nov 23, 2020 6:00am EST
CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms Nov 17, 2020 9:00am EST
CytoDyn Announces Registration of Trademark for VYROLOGIX in Several Countries Nov 16, 2020 6:05am EST
Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy Nov 16, 2020 6:00am EST
CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials Nov 11, 2020 6:00am EST
CytoDyn to Hold Webcast on November 5 to Update Clinical and Regulatory Developments Nov 02, 2020 1:16pm EST
U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy Oct 27, 2020 12:00am EDT
U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy Oct 26, 2020 11:59pm EDT
